“The market is real; the promised genetic edge remains far less certain.”
“We are already entering a market where affluent parents can pay about $30,000 for IVF-based genetic customization that gives a child a better probabilistic start.”
Some companies already sell embryo-analysis services that use polygenic scores to estimate risks for complex conditions and sometimes predicted traits. These services can be expensive, so the post is reasonable to identify a developing premium market around reproductive genetics.
The content calls this customization and implies a meaningful purchasable advantage. Current services generally select among embryos created through IVF; they do not edit DNA or guarantee desired traits. A long list of screened traits or conditions is not evidence that predictions are accurate enough to produce a better child or a substantial advantage. The specific $30,000 price and 900-trait framing were not independently established here as a standard current offering.
Material. Without explaining that this is embryo ranking rather than gene editing, and that real-world benefit remains unproven, viewers could wrongly conclude that wealthy parents can currently buy reliable genetic enhancement for their children.
Why Clear says this
The central market trend has a factual basis: polygenic embryo screening is commercially available. But the presentation turns experimental, limited risk predictions into an implied ability to customize a superior child. The American Society for Reproductive Medicine says current predictive models are limited and polygenic embryo screening is not ready for clinical use; the ACMG likewise found insufficient evidence of clinical utility. That missing context substantially changes the takeaway.
Evidence
- ASRM describes PGT-P as an emerging predictive tool, not a guarantee, and says current models are limited by insufficient data, gene-environment interactions, and lack of diverse genomic representation.
- ACMG concluded there was insufficient evidence of clinical utility for polygenic embryo selection and did not recommend it as a clinical service at the time of its statement.
- ESHRE endorsed concerns that polygenic-score-based embryo selection in clinical practice is unproven.
- Independent reporting documents a premium commercial offering, but pricing varies by company and package.